Bernardo Rapoport, MD and Ronwyn Van Eeden MBChB, FCP(SA) of The Medical Oncology Centre of Rosebank, Johannesburg, South Africa talk about the future direction for cancer immunotherapy. Creating awareness about different pathophysiology of drugs and their immune-related adverse event profiles is one of the key messages from MASCC 2016. Dr Rapoport believes that in the next 10 years we will see a shift from chemotherapy to immunotherapy as a key cancer treatment option. At the moment, studies with checkpoint inhibitors show ongoing responses in some patients after the treatment is completed. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) and International Society of Ocular Oncology (ISOO) 2016 Annual Meeting on Supportive Care in Cancer held in Adelaide, Australia.